Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Pfizer (PFE) to $44 from $50 and keeps an Equal Weight rating on the shares. Pfizer’s ability to grow Seagen (SGEN) is a show-me story, and Wells Fargo thinks the stock at ~15x 2023 ex-COVID PE is still not cheap for the growth profile, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer Stock (NYSE:PFE): Exceptional Value Near 52-Week Lows
- Astellas Pharma / Pfizer announce positive results from Embark trial of XTANDI
- Pfizer says continues to gather pediatric data on Paxlovid
- FDA advisory committee votes in support of safety and effectiveness of Paxlovid
- FDA advisors back full approval for Pfizer’s Paxlovid in 16-1 vote